Liu Jinrui, Wang Chang'an, Zhao Hongfei, Zhang Jinghua, Ma Jie, Hou Yuanyuan, Zou Hongbin
Department of Renal Transplantation and Nephropathy, The Seventh People's Hospital of Zhengzhou City China.
Department of Blood Transfusion, The Seventh People's Hospital of Zhengzhou City China.
Int J Clin Exp Med. 2015 Aug 15;8(8):11985-95. eCollection 2015.
Locking of central venous catheters with heparin is an accepted practice to maintain catheter patency between dialysis sessions. However, this practice may cause other adverse reactions. Although many studies suggest benefits of other catheter lock solutions over heparin on these grounds, no consensus has been reached for clinical practice. A systematic review and meta-analysis was performed of randomized controlled trials (RCT) that compared antimicrobial-containing or citrate-alone catheter lock solutions with heparin alone in patients undergoing hemodialysis with central venous catheters. Medline, Cochrane Central Register of Controlled Trials from EMBASE, and PubMed were searched for articles published through June 2014. The primary outcomes were catheter-related bacteremia (CRB) and catheter malfunction (CM). The secondary outcomes were bleeding, exit-site infection (ESI), clinical sepsis, and all-cause mortality. Seventeen RCTs met the inclusion criteria. The meta-analysis showed that antimicrobial-containing and citrate-alone lock solutions were superior to heparin for preventing CRB (both P < 0.01). Although antimicrobial-containing lock solutions significantly affected clinical sepsis (P < 0.01), they did not affect ESI, bleeding, or all-cause mortality. Incidence of CM episodes was lower in patients receiving antibiotics + heparin and gentamicin + citrate (both P < 0.05), while other antimicrobial-containing and citrate-alone lock solutions showed no difference. Only citrate-alone lock solutions significantly decreased bleeding and ESI episodes (both P < 0.05). Compared with heparin, antimicrobial-containing lock solutions more effectively prevent CRB and clinical sepsis. Antibiotics + heparin and gentamicin + citrate solutions showing better prevention of CM. Citrate-alone lock solutions result in fewer CRB, bleeding and ESI episodes.
使用肝素封管中心静脉导管是维持透析间期导管通畅的一种公认做法。然而,这种做法可能会引起其他不良反应。尽管许多研究基于这些理由表明其他导管封管溶液比肝素更具优势,但在临床实践中尚未达成共识。我们对随机对照试验(RCT)进行了系统评价和荟萃分析,这些试验比较了含抗菌剂或仅含柠檬酸盐的导管封管溶液与仅使用肝素的情况,研究对象为接受中心静脉导管血液透析的患者。检索了Medline、EMBASE的Cochrane对照试验中央登记库和PubMed,以查找截至2014年6月发表的文章。主要结局为导管相关菌血症(CRB)和导管功能障碍(CM)。次要结局为出血、出口部位感染(ESI)、临床脓毒症和全因死亡率。17项RCT符合纳入标准。荟萃分析表明,含抗菌剂和仅含柠檬酸盐的封管溶液在预防CRB方面优于肝素(两者P均<0.01)。尽管含抗菌剂的封管溶液显著影响临床脓毒症(P<0.01),但它们不影响ESI、出血或全因死亡率。接受抗生素+肝素和庆大霉素+柠檬酸盐的患者CM发作发生率较低(两者P均<0.05),而其他含抗菌剂和仅含柠檬酸盐的封管溶液无差异。仅含柠檬酸盐的封管溶液显著减少出血和ESI发作(两者P均<0.05)。与肝素相比,含抗菌剂的封管溶液能更有效地预防CRB和临床脓毒症。抗生素+肝素和庆大霉素+柠檬酸盐溶液在预防CM方面表现更好。仅含柠檬酸盐的封管溶液导致的CRB、出血和ESI发作较少。